ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tucatinib

Also written as “Tucatinib”, “Tucatinib (ONT-380)” and “ARRY-380, HER2 inhibitor; oral”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasms, led by 4 companies.

Drug pageTucatinib: every studyAll 55 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 12, 202625 company-led studies, 11 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only218 open or runningphase 4since Aug 12, 2026Mar 31, 2008Dec 31, 2026phase 1 · NCT05382364
Criteriumits history only22 open or runningphase 2since Dec 27, 2021Dec 27, 2021Jun 1, 2027phase 2 · NCT05458674
AstraZenecaits history only11 open or runningphase 2since Aug 31, 2020Aug 31, 2020none ahead
Hoffmann-La Roche10 open or runningphase 2since Nov 12, 2020Nov 12, 2020none ahead

Also a collaborator on its studies: Novartis.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2020First study: phase 2 study in Advanced Unresectable or Metastatic Solid MalignancyFirst studyNCT04632992 · 252 enrolled · United States

TargetBeta

ERBB2 →read by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States2CompletedDec 4, 2023252

How it is read

Names in the registry

  • “Tucatinib”, 12 entries
  • “tucatinib”, 11 entries
  • “Tucatinib (ONT-380)”, 1 entry
  • “ARRY-380, HER2 inhibitor; oral”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.